Breast Disease pp 319-323 | Cite as

Occult Primary Breast Cancer with Axillary Metastases

  • Lejla Hadzikadic Gusic
  • Ronald Johnson


Occult primary cancer is defined as the presence of metastatic cancer with an undetectable primary at the time of presentation. Occult breast cancer remains controversial. The low incidence of this cancer precludes prospective trials, and thus evidence-based conclusions must be based on retrospective data.


Occult primary cancer DCIS Sentinel lymph node SLN 


  1. 1.
    Ellerbroek N, Holmes F, Singletary E, Evans H, Oswald M, McNeese M. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer. 1990;66:1461–7.CrossRefGoogle Scholar
  2. 2.
    Galimberti V, Bassani G, Monti S, Simsek S, Villa G, Renne G, Luini A. Clinical experience with axillary presentation breast cancer. Breast Cancer Res Treat. 2004;88:43–7.CrossRefGoogle Scholar
  3. 3.
    Masinghe SP, Faluyi OO, Kerr GR, Kunkler IH. Breast radiotherapy for occult breast cancer with axillary nodal metastases-does it reduce the local recurrence rate and increase overall survival? Clin Oncol. 2011;23:95–100.CrossRefGoogle Scholar
  4. 4.
    Merson M, Andreola S, Galimberti V, Bufalino R, Marchini S, Veronesi U. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer. 1992;70(2):504–8.CrossRefGoogle Scholar
  5. 5.
    Montagna E, Bagnardi V, Rotmensz N, Viale G, Cancello G, Mazza M, et al. Immunohistochemically defined subtypes and outcome in Occult Breast Carcinoma with axillary presentation. Breast Cancer Res Treat. 2011;129:867–75.CrossRefGoogle Scholar
  6. 6.
    Surveillance Epidemiology and End Results (SEER) Database. Available at
  7. 7.
    Siegel R, Naishadham D, Jemal A. Cancer statistics. Cancer J Clin. 2012;62:10–29.CrossRefGoogle Scholar
  8. 8.
    Varadarajan R, Edge SB, Yu J, et al. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology. 2006;71:456–9.CrossRefGoogle Scholar
  9. 9.
    Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases. Arch Surg. 1990;125:210–4.CrossRefGoogle Scholar
  10. 10.
    Cameron HC. Some clinical facts regarding mammary cancer. Br Med J. 1909;1:577–82.CrossRefGoogle Scholar
  11. 11.
    National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. v2.2015. Available at
  12. 12.
    Barton SR, Smith IE, Kirby AM, Ashley S, Walsh G, Parton M. The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer. 2011;47:2099–106.CrossRefGoogle Scholar
  13. 13.
    Green FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al. American joint committee on cancer: cancer staging handbook. 6th ed. New York: Springer; 2002. p. 255–81.Google Scholar
  14. 14.
    Khandelwal AK, Garguilo GA. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and Review of the Literature. Am J Surg. 2005;190:609–13.CrossRefGoogle Scholar
  15. 15.
    Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116:4000–6.CrossRefGoogle Scholar
  16. 16.
    Wang X, Zhao Y, Cao X. Clinical benefits of mastectomy on treatment of occult breast carcinoma presenting axillary metastases. Breast J. 2010;16(1):32–7.CrossRefGoogle Scholar
  17. 17.
    Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Lejla Hadzikadic Gusic
    • 1
    • 2
    • 3
  • Ronald Johnson
    • 4
  1. 1.Division of Surgical Oncology, Department of SurgeryLevine Cancer Institute, Carolinas Medical CenterCharlotteUSA
  2. 2.Department of SurgeryCarolinas Medical CenterCharlotteUSA
  3. 3.Magee-Womens Hospital, UPMCPittsburghUSA
  4. 4.Division of Surgical Oncology, Department of SurgeryMagee-Womens Hospital, UPMCPittsburghUSA

Personalised recommendations